Nocardia concava was identified as a new species in 2005; however, the clinical manifestations of Nocardia concava infection have yet to be clarified. We herein present the case of an immunosuppressed patient who developed disseminated nocardiosis caused by N. concava with multiple abscesses in the lungs, cutis, subcutaneous tissue, skeletal muscles and kidneys accompanied by central nervous system involvement, including meningitis and ventriculitis. The patient was cured with appropriate treatment including linezolid after testing for susceptibility. Linezolid should be considered as an alternative agent for treating disseminated nocardiosis because of its effective distribution to multiple sites.
Introduction
Nocardia concava was first isolated in two cases of cutaneous infection in Japan and was identified as a new species in 2005 (1) . A case of systemic nocardiosis caused by N. concava in which multiple abscesses were observed in the lungs and liver was first reported in China (2) . In spite of improvements achieved with combination antibiotic therapy, that patient died due to deterioration as a result of infection and multiple organ failure. Since that case is the only reported case of nocardiosis caused by N. concava, the clinical manifestations of N. concava infection have not been clarified. In addition, the antimicrobial susceptibility patterns of Nocardia vary depending on the species (3) (4) (5) . Resistance to β-lactam agents varies between 20% and 50%, although β-lactamase activity is observed in all Nocardia isolates. Therefore, identifying Nocardia species is indispensable for selecting appropriate antibiotics. Disseminated nocardiosis is defined as two noncontiguous sites of involvement that are disseminated from a pulmonary or cutaneous focus (3, 6) . Because Nocardia spreads to various organs, including the central nervous system (CNS), bones, muscles, joints, kidneys and heart valves, nocardiosis patients present with a wide range of nonspecific clinical features, making it difficult to distinguish the disease from other severe infections and malignancies. Detection of Nocardia species has been reported to be rare in spite of hematogenous spread because several weeks of culture is required for identification (7) . In general, blood cultures are performed for only one week, thus resulting in less frequent identification of Nocardia species.
We herein present a case of an immunosuppressed patient who developed disseminated nocardiosis caused by N. concava with multiple abscesses and CNS involvement, including meningitis and ventriculitis. Although a diagnosis of metastatic carcinoma was initially suspected based on the clinical manifestations and radiological findings, N. concava was 
Case Report
The patient was a 73-year-old man with a 12-year history of multiple myeloma. Two months after receiving high-dose dexamethasone for multiple myeloma exacerbation, the patient noticed multiple red nodules and erythemas with pain, swelling and warmth on his precordia and bilateral extremities. Fever, anorexia and general fatigue subsequently occurred, and he was admitted to the hospital. Prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) was not administered. The patient's body weight was 66 kg and his height was 161 cm. A physical examination revealed a temperature of 39.2 . Neither crackles nor heart murmurs were heard. Red nodules with pustules in the center were observed on the left superior eyelid, precordia, left arm, both thighs and precordial region. An alert cognitive state of consciousness was observed, and other neurological evaluations revealed no remarkable findings. A laboratory examination revealed a white cell count of 10.4×10 3 /μL with neutrophil predominance (87%). The remaining laboratory data were as follows: hemoglobin: 10.5 g/dL, serum creatinine: 0.93 mg/ dL, albumin: 1.3 g/dL, lactate dehydrogenase: 190 U/L, sodium: 122 mEq/L and C-reactive protein: 15.06 mg/dL. The serum levels of IgG and β-2 microglobulin were 2,310 mg/ dL and 4.8 μg/mL, respectively, which had remained unchanged over the previous six months. In spite of positive test results for serum human T lymphotrophic virus type I (HTLV-I) antibodies, no abnormal lymphocytes were noticed in the bone marrow or peripheral blood. An arterial blood A whole-body computed tomography scan performed on admission revealed a huge mass in the right lung and multiple nodular lesions in both lungs (Fig. 1A) , subcutaneous tissue, skeletal muscles (Fig. 1B, C ) and both kidneys (Fig. 1D) . Magnetic resonance imaging revealed multiple brain abscesses ( Fig. 1E ) with meningitis and ventriculitis (Fig. 1F) . The cerebrospinal fluid (CSF) cell count was 1,698 cells/μL (100% neutrophils), the protein concentration was 76.0 mg/ mL and the glucose concentration was 16 mg/mL. Branching Gram-positive and partially acid-fast positive rods were observed in bronchoalveolar lavage fluid obtained from the right upper bronchial tree and in a skin biopsy specimen obtained from a nodule of the precordia, thus suggesting the presence of Nocardia species. No pathogens were detected at three time points (admission, 13 and 25 days) in six sets of blood cultures. Upon further examination, the Nocardia species isolated from the skin biopsy specimen was found to include branching, Gram-positive, beaded, filamentous and partially acidfast positive rods that grew well at 37 but not at 45 on blood agar plates. The biochemical characteristics of the bacterium included decomposition of adenine, hypoxanthine, tyrosine, urea and xanthine but not casein. Acid formations from arabinose, galactose, glucose, inositol and mannose were observed. The strain contained mycolic acid and mesodiaminopimeric acid, confirming that the bacterium belongs to the Nocardia genus (1). The isolate was confirmed to the species level with a 16S rRNA gene analysis. PCR amplification of the 16S rRNA gene was performed using primers 8UA (5'-AGAGTTTGATCMTGGCTCAG-3') and 1485B (5'-TACGGTTACCTTGTTACGAC-3'). The sequences were compared with sequences published in the GenBank database using the BLAST algorithm, with the closest match obtained for N. concava (pairwise similarity to IFM 0354, 99.9%; IFM 0576, 99.2%; EF 177464, 99.6%). Because it has been reported that there are multiple differing copies within the variable region of the 16S rRNA in Nocardia isolates (8), we also confirmed the identity of the bacterium by sequencing the gyrase B-encoding gene (gyrB), as previously described (9) . A similar evaluation using BLAST showed that the gyrB of the isolate from our patient (Accession No. AB685341) was most similar to that of N. concava, which together with the result of the 16S rRNA analysis confirmed that the isolate was N. concava. The minimum inhibitory concentrations (MICs) were determined using the broth microdilution method according to CLSI guidelines (10) . The MICs for amikacin, ciprofloxacin, trimethoprim, linezolid and minocycline were ! 2.0, 1.0, 2.0, 4.0 and ! 1.0 μg/mL,respectively; however, those for ceftriaxone and imipenem were 32.0 and >16.0 μg/mL, respectively (Table) .
Considering these findings, we diagnosed the patient with disseminated nocardiosis. The brain abscesses were too numerous and the masses too small to consider surgical treatment. Because the chemical sensitivity was unknown, we initially administered empirical antibiotic therapies using TMP-SMX, ceftriaxone and amikacin. However, the lung lesions increased due to pulmonary edema caused by anemia and hypoalbuminemia as well as deterioration of nocardiosis, and the patient's level of consciousness worsened. Fifteen days after admission, mechanical ventilator support became necessary due to hypoxemic respiratory failure. Although the antibiotic treatment was changed to TMP-SMX, ciprofloxacin, amikacin and minocycline based on antibiotic susceptibility tests (Table) , the patient's condition did not improve. Finally, treatment with linezolid was started along with TMP-SMX and minocycline, following which all of the patient's signs and symptoms, including the CSF findings, improved remarkably (Fig. 2) . The patient was weaned from the ventilator 20 days after treatment with linezolid was started. He was treated with linezolid, TMP-SMX and minocycline for a total of approximately two and one-half months. Following this, we selected oral administration of levofloxacin and minocycline because long-term treatment for nocardiosis is necessary. The nocardiosis has not recurred within one year and a half after the initiation of treatment.
Discussion
Identifying pathogenic species using biochemical and molecular analyses is necessary in order to select appropriate antibiotics, especially in cases of nocardiosis. The antimicrobial susceptibility patterns of Nocardia differ geographically and vary depending on the species (3) (4) (5) . Among 15 Nocardia strains, the frequency of cases resistant to β-lactam agents is 33%, 20-52% and 20-30% for amoxicillin, ceftriaxone and imipenem, respectively (4, 5) . In addition, the microbiological and clinical spectrum of nocardiosis has been altered due to improved identification of the isolates. The application of molecular techniques such as the se- 
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quencing of 16S rRNA has led to an increase in the number of distinct clinically significant species of this genus (11, 12) . A phylogenetic analysis based on a sequence analysis of 16S rRNA led to the identification of a novel species of Nocardia, N. concava (1) . The N. concava isolated in our case evidenced resistance to imipenem as two reference strains, IFM0354 and IFM 0576 (1) . Although the MIC values for TMP-SMX, ciprofloxacin and amikacin evidenced susceptibility, these antibiotics did not improve the patient's condition until linezolid was added. There are two possible explanations for this: the immunity of the host, who had multiple myeloma and was an HTLV-I carrier; and the different bioavailability of linezolid compared with other antibiotics. Multiple myeloma is accompanied by serious abnormalities in humoral immunity. HTLV-I-infected carriers have been reported to have immune deficiencies associated with an increased risk of certain infectious disease complications (13) . Linezolid, the first oxazolidinone, can be used for treating infections with most Gram-positive bacteria. The characteristics of this drug include a unique mechanism of action that involves the inhibition of the formation of a functional 70S initiation complex in the 50S bacterial ribosomal subunit and good distribution to multiple sites including the CNS, lungs and skin (14) . These characteristics might have contributed to the rapid improvement observed in our case. According to a recent review, linezolid is associated with cure or improvement in all reviewed cases of nocardiosis (15) . However, its use was discontinued in the majority of cases due to the development of serious complications, including myelosuppression and peripheral neuropathy. Fortunately, our patient did not suffer from such adverse effects, and effective treatment was accomplished.
In conclusion, N. concava can cause disseminated infection in immunocompromised patients. When the response to β-lactam is poor, linezolid should be considered as an alternative agent for treating disseminated nocardiosis due to its effective distribution to multiple sites. Because Nocardia evidences a species-specific drug susceptibility profile, appropriate antibiotics should be selected based on antibiotic susceptibility tests.
